SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer

Cancer Treatment Reviews

Volumn 36, Issue 2, 2010, Pages 177-184

  Saad, Fred ^a   Lipton, Allan ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Bone metastases; Bosutinib; Breast cancer; Dasatinib; Prostate cancer; Saracatinib; SRC inhibitors; SRC kinase

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 7 [4 [2 (2 METHOXYETHYLAMINO)ETHOXY]PHENYL] 5 (4 METHOXYPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; ANASTROZOLE; AP 23451; AZM 475271; BOSUTINIB; CAPECITABINE; CGP 77675; DASATINIB; DOCETAXEL; EXEMESTANE; FULVESTRANT; LETROZOLE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NON RECEPTOR PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; SRC KINASE INHIBITOR; SRC PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADVANCED CANCER; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG TARGETING; HORMONE RECEPTOR INTERACTION; HUMAN; MORBIDITY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROSTATE CANCER; REVIEW; SOLID TUMOR; BLOOD; BONE TUMOR; BREAST TUMOR; DISEASE COURSE; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; MALE; METASTASIS; PATHOLOGY; PROSTATE TUMOR;

BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; SRC-FAMILY KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 77950616066     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.11.005     Document Type: Review

References (107)

1. Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther 2007, 4:92-100.
2. Kingsley L.A., Fournier P.G., Chirgwin J.M., Guise T.A. Molecular biology of bone metastasis. Mol Cancer Ther 2007, 6:2609-2617.
3. Roodman G.D. Mechanisms of bone metastasis. New Engl J Med 2004, 350:1655-1664.
4. Fernandez-Tresguerres-Hernandez-Gil I., obera-Gracia M.A., del-Canto-Pingarron M., Blanco-Jerez L. Physiological bases of bone regeneration II. The remodeling process. Med Oral Patol Oral Cir Bucal 2006, 11:E151-E157.
5. Siclari V.A., Guise T.A., Chirgwin J.M. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev 2006, 25:621-633.
6. Zhau H.E., Odero-Marah V., Lue H.W., et al. Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis 2008, 25:601-610.
7. Saad F., Lipton A., Cook R., Chen Y.M., Smith M., Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110:1860-1867.
8. Saad F., Adachi J.D., Brown J.P., et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008, 26:5465-5476.
9. Brown J.E., Neville-Webbe H., Coleman R.E. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004, 11:207-224.
10. Lipton A., Cook R., Saad F., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113:193-201.
11. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
12. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
13. Saad F., Higano C.S., Sartor O., et al. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer 2006, 4:257-262.
14. Saad F., Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 2007, 34:S17-S23.
15. Saad F. Bone-directed treatments for prostate cancer. Hematol Oncol Clin North Am 2006, 20:947-963.
16. Caraglia M., Santini D., Marra M., Vincenzi B., Tonini G., Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006, 13:7-26.
17. Lipton A. Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 2008, 34(Suppl. 1):S25-S30.
18. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New Engl J Med 2009, 360:679-691.
19. Saad F., Markus R., Goessl C. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases. BJU Int 2008, 101:1071-1075.
20. Fizazi K., Lipton A., Mariette X., et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009, 27:1564-1571.
21. Lipton A., Steger G.G., Figueroa J., et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007, 25:4431-4437.
22. Body JJ, Lipton A, Gralow J, et al. Effects of denosumab in patients with bone metastases, with and without previous bisphosphonate exposure. J Bone Miner Res 2009 [Epub August 4].
23. Sutherland K.A., Rogers H.L., Tosh D., Rogers M.J. RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther 2009, 11:R58.
24. Brunton V.G., Frame M.C. Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol 2008, 8:427-432.
25. Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int 2009, 103:434-440.
26. Horne W.C., Neff L., Chatterjee D., Lomri A., Levy J.B., Baron R. Osteoclasts express high levels of pp60c-src in association with intracellular membranes. J Cell Biol 1992, 119:1003-1013.
27. Miyazaki T., Sanjay A., Neff L., Tanaka S., Horne W.C., Baron R. Src kinase activity is essential for osteoclast function. J Biol Chem 2004, 279:17660-17666.
28. de Vries T.J., Mullender M.G., van Duin M.A., et al. The Src Inhibitor AZD0530 Reversibly Inhibits the Formation and Activity of Human Osteoclasts. Mol Cancer Res 2009, 7:476-488.
29. Soriano P., Montgomery C., Geske R., Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991, 64:693-702.
30. Boyce B.F., Yoneda T., Lowe C., Soriano P., Mundy G.R. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992, 90:1622-1627.
31. Marzia M., Sims N.A., Voit S., et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 2000, 151:311-320.
32. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997, 13:513-609.
33. Belsches-Jablonski A.P., Biscardi J.S., Peavy D.R., Tice D.A., Romney D.A., Parsons S.J. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 2001, 20:1465-1475.
34. Biscardi J.S., Belsches A.P., Parsons S.J. Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol Carcinogen 1998, 21:261-272.
35. Lesslie D.P., Summy J.M., Parikh N.U., et al. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer 2006, 94:1710-1717.
36. Sekharam M., Nasir A., Kaiser H.E., Coppola D. Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro. Anticancer Res 2003, 23:1517-1524.
37. Chang Y.M., Bai L., Liu S., Yang J.C., Kung H.J., Evans C.P. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008, 27:6365-6375.
38. Goldenberg-Furmanov M., Stein I., Pikarsky E., et al. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res 2004, 64:1058-1066.
39. Ottenhoff-Kalff A.E., Rijksen G., van Beurden E.A., Hennipman A., Michels A.A., Staal G.E. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 1992, 52:4773-4778.
40. Park S.I., Zhang J., Phillips K.A., et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008, 68:3323-3333.
41. Posadas E.M., Al-Ahmadie H., Robinson V.L., et al. FYN is overexpressed in human prostate cancer. BJU Int 2009, 103:171-177.
42. Reissig D., Clement J., Sanger J., Berndt A., Kosmehl H., Bohmer F.D. Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue. J Cancer Res Clin Oncol 2001, 127:226-230.
43. Tatarov O., Mitchell T.J., Seywright M., Leung H.Y., Brunton V.G., Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009, 15:3540-3549.
44. Verbeek B.S., Vroom T.M., driaansen-Slot S.S., et al. C-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996, 180:383-388.
45. Evans CP, Bai L, Kung H, Yang JC. Effect of the specific Src kinase inhibitor AZD0530 on osteolytic lesions in prostate cancer. In: Proc Am Soc Clin Oncol Genitourinary Cancers Symposium; 2008. [abstract 170].
46. Green T.P., Fennell M., Whittaker R., et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 2009, 3:248-261.
47. Nam S., Kim D., Cheng J.Q., et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005, 65:9185-9189.
48. Recchia I., Rucci N., Festuccia C., et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer 2003, 39:1927-1935.
49. Finn R.S., Dering J., Ginther C., et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/" triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007, 105:319-326.
50. Jallal H., Valentino M.L., Chen G., Boschelli F., Ali S., Rabbani S.A. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007, 67:1580-1588.
51. Nautiyal J., Majumder P., Patel B.B., Lee F.Y., Majumdar A.P. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett 2009, 283:143-151.
52. Asim M., Siddiqui I.A., Hafeez B.B., Baniahmad A., Mukhtar H. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene 2008, 27:3596-3604.
53. Migliaccio A., Castoria G., Di D.M., et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 2000, 19:5406-5417.
54. Auricchio F., Migliaccio A., Castoria G. Sex-steroid hormones and EGF signalling in breast and prostate cancer cells: targeting the association of Src with steroid receptors. Steroids 2008, 73:880-884.
55. Migliaccio A., Di D.M., Castoria G., et al. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res 2005, 65:10585-10593.
56. Migliaccio A., Varricchio L., De F.A., et al. Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth. Oncogene 2007, 26:6619-6629.
57. Varricchio L., Migliaccio A., Castoria G., et al. Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptide. Mol Cancer Res 2007, 5:1213-1221.
58. Chen Y., Guggisberg N., Jorda M., et al. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin Cancer Res 2009, 15:3396-3405.
59. Herynk M.H., Beyer A.R., Cui Y., et al. Cooperative action of taxoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 2006, 5:3023-3031.
60. Hiscox S., Morgan L., Green T., Nicholson R.I. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer 2006, 13:53-59.
61. Mellado B., Codony J., Ribal M.J., Visa L., Gascon P. Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. Clin Transl Oncol 2009, 11:5-10.
62. Hiscox S., Morgan L., Green T.P., Barrow D., Gee J., Nicholson R.I. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006, 97:263-274.
63. Lee L.F., Guan J., Qiu Y., Kung H.J. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 2001, 21:8385-8397.
64. Lee L.F., Louie M.C., Desai S.J., et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 2004, 23:2197-2205.
65. Planas-Silva M.D., Bruggeman R.D., Grenko R.T., Stanley S.J. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun 2006, 341:73-81.
66. Riggins R.B., Thomas K.S., Ta H.Q., et al. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 2006, 66:7007-7015.
67. Unni E., Sun S., Nan B., et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 2004, 64:7156-7168.
68. Hiscox S., Jordan N.J., Morgan L., Green T.P., Nicholson R.I. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metastasis 2007, 24:157-167.
69. Yang J.C., Ok J.H., Busby J.E., Borowsky A.D., Kung H.J., Evans C.P. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 2009, 69:151-160.
70. Hiscox S., Jordan N.J., Smith C., et al. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat 2009, 115:57-67.
71. Boyer B., Bourgeois Y., Poupon M.F. Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene 2002, 21:2347-2356.
72. Myoui A., Nishimura R., Williams P.J., et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003, 63:5028-5033.
73. Rucci N., Recchia I., Angelucci A., et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice. implications for therapy. J Pharmacol Exp Ther 2006, 318:161-172.
74. Zhang X.H., Wang Q., Gerald W., et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16:67-78.
75. Wang X.D., Reeves K., Luo F.R., et al. Identification of candidate predictive, surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection, efficacy monitoring. Genome Biol 2007, 8:R255.
76. Yano A., Tsutsumi S., Soga S., et al. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci USA 2008, 105:15541-15546.
77. Huang F., Reeves K., Han X., et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007, 67:2226-2238.
78. Pichot C.S., Hartig S.M., Xia L., et al. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 2009, 101:38-47.
79. Brownlow N., Mol C., Hayford C., Ghaem-Maghami S., Dibb N.J. Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 2009, 23:590-594.
80. Shor A.C., Keschman E.A., Lee F.Y., et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007, 67:2800-2808.
81. Vandyke K., Dewar A.L., Farrugia A.N., et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009, 23:994-997.
82. Vultur A., Buettner R., Kowolik C., et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 2008, 7:1185-1194.
83. Zhang Y.X., Knyazev P.G., Cheburkin Y.V., et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 2008, 68:1905-1915.
84. Shakespeare W.C., Wang Y., Bohacek R., et al. SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity. Chem Biol Drug Des 2008, 71:97-105.
85. Evans CP, Lara PN, Kung H, Yang JC. Activity of the Src-kinase inhibitor AZD0530 in androgen-independent prostate cancer (AIPC): pre-clinical rationale for a phase II trial. J Clin Oncol 2006;24 (Suppl.):640 [abstract 14542].
86. Recchia I., Rucci N., Funari A., et al. Reduction of c-Src activity by substituted 5, 7-diphenyl-pyrrolo[2, 3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. Bone 2004, 34:65-79.
87. Olayioye M.A., Badache A., Daly J.M., Hynes N.E. An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway. Exp Cell Res 2001, 267:81-87.
88. Missbach M., Jeschke M., Feyen J., et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 1999, 24:437-449.
89. Garcia R., Bowman T.L., Niu G., et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20:2499-2513.
90. Lombardo L.J., Lee F.Y., Chen P., et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2- methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658-6661.
91. Puttini M., Coluccia A.M., Boschelli F., et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006, 66:11314-11322.
92. Hennequin L.F., Allen J., Breed J., et al. N-(5-chloro-1, 3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2 H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 2006, 49:6465-6488.
93. Gautschi O., Tepper C.G., Purnell P.R., et al. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res 2008, 68:2250-2258.
94. Mendiratta P., Mostaghel E., Guinney J., et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009, 27:2022-2029.
95. Journe F, Kheddoumi N, Chaboteaux C, Sotiriou C, Piccart M, Body JJ. The Src inhibitor dasatinib inhibits breast cancer cell growth in vitro and exerts synergistic effects with bisphosphonates. Bone 2008;42:S96-7 [abstract 174].
96. Yu EY, Massard C, Gross M, et al. A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CA180085). J Clin Oncol 2009;27(Suppl.):270s [abstract 5147].
97. Yu EY, Wilding G, Posadas E, et al. Dasatinib in patients with hormone-refractory progressive prostate cancer: a phase II study. J Clin Oncol 2008;26 (Suppl.):288s [abstract 5156].
98. Araujo J, Armstrong AJ, Braud EL, et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180086). J Clin Oncol 2009;27(Suppl.):249s [abstract 5061].
99. Finn RS, Bengala C, Ibrahim N, et al. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059. In: Proceedings of the SABCS; 2008 [abstract 3118].
100. Mayer E, Baurain J, Sparano J, et al. Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: phase II study CA180088. J Clin Oncol 2009;27(Suppl.);43s [abstract 1011].
101. Somlo G, Atzori F, Strauss L, et al. Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): phase I study CA180004. J Clin Oncol 2009;27(Suppl.);43s [abstract 1012].
102. Lara P.N., Longmate J., Evans C.P., et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California cancer consortium study. Anticancer Drugs 2009, 20:179-184.
103. Campone M, Bondarenko I, Brincat S, et al. Preliminary results of a phase 2 study of bosutinib (SKI-606), a dual Src/Abl kinase inhibitor, in patients with advanced breast cancer. In Proceedings of the SABCS; 2007 [abstract 6062].
104. Smith M.R., Cook R.J., Coleman R., et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 2007, 70:315-319.
105. Wildes TM, Procknow E, Weilbaecher K, Vij R. Effect of dasatinib on bone metabolism in multiple myeloma. J Clin Oncol 2008;26.
106. Hannon RA, Clack G, Rimmer M, et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple ascending dose phase I trial. J Bone Miner Res 2009 [Epub Sep. 23].
107. Tabernero J, Cervantes A, Hoekman K, et al. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers. J Clin Oncol 2007;25 (Suppl):143s [abstract 3520].